 NantHealth, Inc. NASDAQ: NH, a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis, today presented a novel artificial intelligence platform for aiding pathologists in image-based lung cancer subtyping at the Society for Imaging Science and Technologys International Symposium on Electronic Imaging 2020. This novel machine vision software platform accurately subtypes lung cancer pathology and achieves high concordance with analysis performed by trained medical pathologists. 